Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention Joint Metastasis Research Society-AACR Conference on Metastasis
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kindler-Röhrborn, A.
Right arrow Articles by Rajewsky, M. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kindler-Röhrborn, A.
Right arrow Articles by Rajewsky, M. F.
[Cancer Research 60, 4756-4760, September 1, 2000]
© 2000 American Association for Cancer Research

Advances in Brief

Suppression of Ethylnitrosourea-induced Schwannoma Development Involves Elimination of neu/erbB-2 Mutant Premalignant Cells in the Resistant BDIV Rat Strain1

Andrea Kindler-Röhrborn2, André B. Kind2, Bernd U. Koelsch, Christine Fischer and Manfred F. Rajewsky3

Institute of Cell Biology (Cancer Research), University of Essen Medical School and West German Cancer Center Essen, D-45122 Essen, Germany [A. K-R., A. B. K., B. U. K., M. F. R.], and Institute of Human Genetics, University of Heidelberg, Im Neuenheimer Feld 328, D-69120 Heidelberg, Germany [C. F.]


   ABSTRACT
Top
 ABSTRACT
Introduction
 Materials and Methods
 Results
 Discussion
 REFERENCES
 
Contrary to the response of rats of the highly sensitive inbred strain BDIX, BDIV rats are resistant to the induction of malignant schwannomas by exposure to the alkylating N-nitroso carcinogen N-ethyl-N-nitrosourea (EtNU). In BDIX rats, a point mutation at nucleotide 2012 in the transmembrane region of the neu/erbB-2 gene has proved to be a very early marker of initiated Schwann precursor cells with an elevated risk of malignant transformation, and is diagnostic of the resulting schwannomas. To gain insight into the cellular and molecular mechanisms responsible for the resistance of the BDIV strain, comparative quantitative neu mutation analyses combined with histomorphological studies were performed on the trigeminal nerves of EtNU-treated BDIV and BDIX rats as well as on their (BDIX x BDIV) F1 progeny. It was found that neu-mutant Schwann cells are initially present at comparable frequency in the trigeminal nerves of both resistant and sensitive animals. Contrasting with the progressive multiplication of mutant Schwann cells in BDIX trigeminal nerves, however, the numbers of mutant cells began to decrease during the intermediary phase of the carcinogenic process in BDIV animals, and premalignant neu-mutant cells were no longer detectable by the time BDIX rats developed full-blown trigeminal schwannomas. The resistance of BDIV rats thus involves the elimination of initiated neu-mutant Schwann cells during the postinitiation period of EtNU-induced schwannomagenesis via mechanisms that remain to be clarified.


   Introduction
Top
 ABSTRACT
 Introduction
Materials and Methods
 Results
 Discussion
 REFERENCES
 
Depending on their genetic background, inbred rodent strains exhibit a broad spectrum of sensitivity toward the induction of malignant tumors by specific carcinogens, ranging from high susceptibility to almost entire resistance (1) . Although humans, too, may be intrinsically resistant to carcinogenesis, the contribution to cancer resistance in humans is much more difficult to assess because the individual exposure to carcinogens is usually unknown and multigenic inheritance as well as low penetrance preclude the detection of human gene carriers (1 , 2) . Nevertheless, at least part of the responsible gene homologues may be identified in rodent models (3) . A number of resistance loci for different types of tumors have been mapped in appropriate genetic crosses of mice (1) and rats (4 , 5) . With a single exception (6) , however, none of the genes involved has thus far been identified. In principle, genes conferring differential resistance toward the development of tumors can exert a wide variety of functions and act during different phases of the process of carcinogenesis (7, 8, 9, 10) . Functional studies on resistance mechanisms may thus lead to a better understanding of the multistep process of carcinogenesis and may facilitate the identification of relevant candidate genes and pathways for cancer preventive intervention.

Rats of the inbred BD strains (11) provide an excellent model for the study of resistance to chemically induced carcinogenesis in the peripheral and central nervous system because these strains exhibit differential sensitivity toward the induction of neural tumors by pre- or perinatal pulse-exposure to EtNU4 (12 , 13) . Thus, BDIX rats develop malignant schwannomas, predominantly of the trigeminal nerves, with an incidence >85%, whereas BDIV rats are entirely resistant (12 , 14) . Schwannoma development is strongly suppressed in (BDIX x BDIV) F1 rats, consistent with a dominant resistance gene with decreased penetrance and/or with polygenic inheritance. On the basis of targeted linkage mapping in genetic crosses of BDIX and BDIV rats, we have recently reported a locus on chromosome 10 that is associated with susceptibility/resistance toward schwannoma development (14) .

A transversion mutation at nucleotide 2012 in the transmembrane region of the neu/erbB-2 gene is likely to be the initial event in EtNU-induced schwannoma development in sensitive strains of rats (15) .5 This mutation (16) is diagnostic of EtNU-induced rat schwannomas (15 , 17) and in the process of oncogenesis characterizes a subset of immature Schwann cells that are mainly located near the nerve-brain junction and exhibit unrestrained proliferative activity in contrast to their differentiating wild-type counterpart cells. neu-mutant Schwann cells are, therefore, at high risk of progressing toward the expression of fully malignant phenotypes.

Different from other animal models of strain-specific oncogenesis that rely on the detection of complex histomorphological alterations as premalignant lesions (10 , 18) , the identification of mutant neu-alleles in the DNA of microdissected trigeminal nerve tissue allows us to reproducibly quantify premalignant cells before any morphological changes become detectable as well as later on during the process of carcinogenesis. Because neu mutation-tagged cells can be followed regardless of alterations in cell morphology or cell migration, the rat model of EtNU-induced carcinogenesis in the trigeminal nerve is particularly well suited to gain insight into potential resistance mechanisms operating in a stage-specific manner.

In the present study, we have quantified the neu-mutant alleles in the trigeminal nerves of resistant BDIV and predominantly resistant (BDIX x BDIV) F1 animals in comparison with the sensitive BDIX rats as a function of time after exposure to EtNU on postnatal day 1 in parallel to histomorphological analyses.


   Materials and Methods
Top
 ABSTRACT
 Introduction
 Materials and Methods
Results
 Discussion
 REFERENCES
 
Animals and Carcinogen Treatment.
Inbred BDIX and BDIV rats (11) , as well as first-generation crosses of genders in both orientations [(BDIX x BDIV) F1 and (BDIV x BDIX) F1], were kept under standard conditions in the animal facility of the Institute of Cell Biology (Cancer Research), University of Essen Medical School. Rats of both strains and their F1 progeny received a single s.c. injection of EtNU (80 µg/g body weight) 24 h postnatally (19) . Control animals were injected with buffer only.

Preparation of Histological Samples.
From postnatal day 30 onward, groups of 3–10 rats were sacrificed with CO2 at defined intervals. The intracranial portions of the trigeminal nerves were dissected out under a stereo operation microscope, snap frozen in liquid nitrogen, and stored at -80°C until cryosectioning (15) . In most cases, both nerves were used. Frozen sections (8 µm) were dried and stained with Mayer’s hemalum.

Microdissection.
To reproducibly analyze trigeminal nerve tissue near the nerve-brain junction known to contain neu-mutant premalignant cells (15) , this area was microdissected from hemalum-stained longitudinal sections of the central nerve region. Adjacent brain tissue and the meninges were removed with a sterile needle under the stereo microscope, and a 1-mm-wide tissue specimen was then transferred into a PCR tube.

Quantitative neu Mutation Analysis in Microdissected Nerve Tissue.
Fluorescence-labeled PCR amplification of a 129 bp neu gene fragment from microdissected material was carried out in a total volume of 25 µl. Final concentrations of deoxynucleotide triphosphates were 0.2 mM. Primer 402e (5'-GCC AGC CCG GTG ACA TTC ATC ATT G-3') and FITC-labeled primer 412 (5'-fluoro-GCA GCC TAC GCA TCG TAT ACT TCC G-3'; Life Technologies, Karlsruhe, Germany), respectively, were used at 0.1 µM concentrations. Taq polymerase (Pharmacia Biotech, Freiburg, Germany) 0.5 units were added per reaction. Amplification was performed in a Trio-Thermocycler (Biometra, Göttingen, Germany) in the dark, using a profile of 0.6 min at 94°C, 1 min at 65°C, and 1 min at 72°C for 45 cycles, with a final 10-min extension at 72°C. For quantitative restriction fragment length analysis, 1 µl of each PCR product was digested with 0.5 unit of MnlI (recognition sequence, 5'-CCTC(N)7; MBI Fermentas, St. Leon-Rot, Germany) for 3 h at 37°C. 0.3 µl of the digested PCR product was combined with 4 µl loading buffer, denatured at 90°C for 10 min, and placed on ice. Samples were electrophoresed on denaturing 6% polyacrylamide gels [acrylamide:N,N'-methylenebisacrylamide, 19:1; Ready Mix Gel, A.L.F. grade, Pharmacia Biotech] in TBE buffer on an A.L.F. DNA Sequencer (Pharmacia Biotech).

For each sample, fluorescence-labeled fragments [wild-type allele (129 bp), mutant allele (104 bp)] were quantified by calculating the peak integrals (Fragment Manager program; Pharmacia Biotech), and their ratios were determined.

Statistical Analysis.
Each trigeminal nerve was regarded as an independent unit of observation with respect to the fraction of mutant neu alleles. Group comparisons were performed using the nonparametric Wilcoxon test as implemented in SAS V.6.12 on PC. Pointwise Pvalues were reported.


   Results
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
Discussion
 REFERENCES
 
Quantification of Mutant neu Alleles by Fluorescence-labeled PCR Fragment Length Analysis.
To comparatively determine the amounts of neu-mutant alleles in both rat strains, length analyses of PCR amplified fluorescence-labeled fragments of the neu gene were performed on an automated DNA sequencer. The characteristic T:A->A:T transversion mutation at nucleotide 2012 of the neu gene was detected by the resulting additional restriction site for MnlI. Calibration was performed by measuring the ratio of wild-type to mutant alleles in defined mixtures of a homozygously mutant schwannoma cell line with a fibroblast cell line carrying two wild-type neu alleles. The detection limit for reliable quantitation of mutant alleles with an SD of <1% was 5%. Fig. 1Citation shows examples of fragment length analyses of trigeminal nerve DNA from EtNU-treated and control animals. Mutant neu alleles could be detected from day 30 after EtNU exposure onward.



View larger version (21K):
[in this window]
[in a new window]
  		Fig. 1. neu gene fluorescence-labeled PCR fragment length analysis after MnlI digestion using an ALF DNA sequencer. The integral of the 129-bp peak represents the amount of wild-type neu, and the integral of the 104-bp peak represents the amount of the MnlI-cleaved mutant gene. A, template DNA from a BDIV rat at 80 days after exposure to EtNU. B, template DNA from a BDIX rat at 190 days after exposure to EtNU. C, template DNA from a mixture of 10% cells from the homozygously neu mutant schwannoma cell line TV1Cb (15) with 90% rat fibroblasts carrying two wild-type neu alleles. D–F, mixtures of TV1Cb cells and rat fibroblasts at a ratio of 20:80, 30:70, and 50:50, respectively.

 
Fractions of Mutant neu Alleles in Trigeminal Nerve Tissue of BDIX and BDIV Rats and Their F1 Progeny Exposed to EtNU on Postnatal Day 1.
Groups of 3–10 BDIV and F1 animals were sacrificed at time intervals of 5 and 10 days between postnatal days 30 and 150 and between postnatal days 30 and 200, respectively, after EtNU- exposure. Thereafter, intervals were extended until day 500. For BDIX rats, fewer time points were chosen because the kinetics of neu-mutant cells had been determined before (15 ; Fig. 2ACitation ). Because neu-mutant cells reside predominantly close to the nerve-brain junction where microtumors arise at later stages (15) , this region was microdissected from 188 trigeminal nerves of 101 BDIV rats, from 126 nerves of 76 BDIX rats, from 223 nerves of 119 (BDIX x BDIV) F1 progeny, and from 222 nerves of 119 (BDIV x BDIX) F1 animals treated previously with EtNU on postnatal day 1. Microdissected tissue was used as a source of DNA for the subsequent fluorescence-labeled PCR.



View larger version (43K):
[in this window]
[in a new window]
  		Fig. 2. Fractions of mutant neu alleles in trigeminal nerve tissue of BDIX (A), BDIV (B), and (BDIX x BDIV) F1 (C) rats, as a function of time after exposure to EtNU on postnatal day 1. The time axis was operationally divided into phases I, II, and III. A, all BDIX rats had developed malignant trigeminal schwannomas by the end of phase II and had been sacrificed by this time. B, all BDIV rats were free of trigeminal schwannomas through phase III. C, 12 cases of macroscopically visible malignant schwannomas were seen at necropsy in phase II.

 
Fig. 2Citation shows the fractions of neu-mutant alleles in the trigeminal nerves of BDIX, BDIV, and (BDIX x BDIV) F1 progeny, as a function of time after exposure to EtNU. The fractions of neu-mutant alleles represent a measure of the numbers of initiated premalignant cells (see "Discussion"). To better describe and summarize the data obtained, the time axis was operationally divided into three phases. During phase I (days 30–100 after EtNU-exposure; Fig. 2ACitation ), the median percentage of mutant alleles was 6.1%, varying between 0 and 26.2%, in the transformation-sensitive BDIX rats. Animals displaying symptoms indicative of trigeminal schwannomas were frequently found to carry one overt tumor only. Therefore, the amount of premalignant cells present at earlier stages may vary considerably between the two nerves. Schwann cells near the nerve-brain junction of the resistant BDIV rat initially (phase I) displayed mutant alleles at higher rates than the Schwann cells of BDIX rats (median, 12.81%; minimum, 0%; maximum, 52.1%; P = 0.0001; Fig. 2BCitation ). During phase II (100–260 days), the frequency of mutant alleles markedly increased in the trigeminal nerves of EtNU-treated BDIX animals (median, 18.3%; minimum, 0%; maximum, 93.2%; Fig. 2ACitation ). However, all of the BDIX rats scheduled to be sacrificed at later time points had to be sacrificed before day 260 because of the presence of trigeminal schwannomas. Tumors, as well as the contralateral nerves in cases where they were intact, were also used for mutation analysis. Contrary to their frequency in BDIX trigeminal nerves, the frequency of neu-mutant alleles continuously decreased in the trigeminal nerves of BDIV rats during phase II and became almost undetectable during phase III (260–500 days), with a median of 2.9, a minimum of 1.1, and a maximum of 27.3 (P = 0.0001; combined data for phases II and III; Fig. 2BCitation ). All of the BDIV rats remained available for analysis without showing any symptoms of trigeminal schwannomas.

In EtNU-treated F1 animals, ~20% of which had been shown previously to exhibit trigeminal tumors (14) , a mixed type of kinetics was observed for the frequency of neu-mutant alleles (Fig. 2C)Citation . Because no significant difference between rats of both orientations of gender was observed, the data were combined. During phase I, the great majority of animals displayed values similar to those determined for BDIV rats (median, 2.9%; minimum, 0%; maximum, 52%). During phase II, high mutation frequencies were observed in a small subgroup of F1 animals, similar to the values detected previously in BDIX rats. However, most animals displayed low frequencies of mutant alleles during phases II and III (median, 5.1; minimum, 0; maximum, 85.1). None of the F1 animals had to be sacrificed before the time points originally scheduled for analysis.

Histomorphological Observations.
The nerve-brain junction was examined histomorphologically in trigeminal nerve sections from EtNU-treated BDIV, BDIX, and (BDIX x BDIV) F1 rats, as well as from untreated control animals. Time intervals were the same as those used for mutation analysis, with the earliest time point at 30 days after EtNU-exposure. neu-mutant cells typically appear as multiple groups of irregularly distributed cells with an increased nuclear:cytoplasmic ratio (early atypical proliferates; Refs. 15 and 20 ).

Histomorphological observations paralleled the findings at the molecular level. As exemplified in Fig. 3Citation , there was no visible difference regarding the frequencies and sizes of early atypical proliferates in the susceptible BDIX and the resistant BDIV rats up to postnatal day 70, whereas untreated control animals neither exhibited morphologically altered cells nor atypical tissue architecture. About 110 days later on, the frequency and size of nests of atypical-looking cells had gradually increased and dominated the nerve-brain junctional area in most of the EtNU-treated BDIX animals. In contrast, the trigeminal nerves of BDIV rats had gradually became devoid of the premalignant cells and at 180 days after EtNU-exposure appeared almost identical to untreated controls. Most trigeminal nerves of F1 animals (data not shown) were histomorphologically indistinguishable from those of their BDIV parents. In a few F1 rats, however, the number of premalignant cells increased during phase II and finally gave rise to full-blown schwannomas.



View larger version (146K):
[in this window]
[in a new window]
  		Fig. 3. Morphological appearance of the trigeminal nerves of BDIX and BDIV rats at different times after exposure to EtNU on postnatal day 1 and of age-matched untreated control animals. A–E, frozen sections of the brain (b)-nerve (n) junction stained with H&E. A and B, trigeminal nerve tissue from BDIX rats at 70 and 180 days, respectively, after exposure to EtNU. C and D, trigeminal nerve tissue from BDIV rats, at 70 and 180 days, respectively, after exposure to EtNU. E and F, trigeminal nerve tissue from age-matched untreated BDIX control animals. Note the similarly increased density of nuclei in A and C in comparison with E. B represents a full-blown schwannoma of a susceptible BDIX rat at 180 days. After the same time interval, D resembles the untreated control tissue F.

 

   Discussion
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
 Discussion
REFERENCES
 
Resistance to the development of chemically induced tumors in inbred rodent strains has been observed frequently (1) . However, neither the underlying biological mechanisms nor the genes involved have thus far been identified.

Using a combination of molecular and histomorphological analyses, we have attempted to obtain information on the cause of the resistance of BDIV rats to the development of EtNU-induced schwannomas, in contrast to the high susceptibility of the BDIX strain. In BDIX rats, immature trigeminal Schwann precursor cells exhibiting a T:A->A:T transversion at nucleotide 2012 of the neu gene transmembrane region are observed from a very early stage of carcinogenesis onward up to the appearance of full-blown malignant schwannomas (15) . These cells are arrested in maturation and, contrary to their differentiating neighboring cells, continue multiplying and, therefore, are at high risk of progressing to the expression of fully malignant phenotypes. The fate of these cells can be monitored along the process of carcinogenesis in vivo. Comparative quantitative neu gene mutation analyses of the trigeminal Schwann cell population of BDIV, (BDIX x BDIV) F1, and BDIX rats as a function of time after exposure to EtNU, paralleled by histomorphological analyses, were thus performed in the present study.

Limitations to an absolute proportionality between the amount of neu-mutant alleles and the number of initiated cells are: (a) the distribution of cell cycle phases in the target cell population; and (b) at a later stage of the carcinogenic process, loss of the wild-type neu allele, as detectable from around day 70 after EtNU-exposure onward.

The neu gene mutation at nucleotide 2012 in trigeminal Schwann cells of BDIV rats was first detected on day 30 after carcinogen exposure and further on throughout phase I (days 30–100) of carcinogenesis (see "Results"). Surprisingly, the frequency of mutant neu alleles detected in BDIV trigeminal nerves during phase I was even higher than in the susceptible BDIX animals. This observation excludes resistance mechanisms based on a strain-specific differential frequency of mutational initiation, caused, e.g., by differential DNA repair capacity. Moreover, a smaller size of the BDIV target cell population, potentially attributable to a different timing of trigeminal development between the two strains, is also unlikely to play a significant role.

The results of the present mutation analyses are mirrored by the histomorphological appearance of BDIV versus BDIX trigeminal nerves during phase I. Around day 70, groups of small round atypical cells that carry the mutant neu gene, as shown previously (15) , accumulated near the trigeminal nerve-brain junction in both BDIV and BDIX rats. Both the frequency and size of these lesions were indistinguishable between the two rat strains. The identical histomorphological appearance of BDIV and BDIX trigeminal nerves during the early phase of carcinogenesis is evidence for the fact that the resistance of BDIV rats is effected by mechanisms acting during later steps in the carcinogenic process. Observations in other experimentally induced rodent tumors, e.g., 1,2-dimethylhydrazine-induced mouse colon tumors (7) and rat mammary tumors induced by N-methyl-N-nitrosourea (8 , 9) , suggest a similar sequence of events.

During phase II (days 100–260) of schwannomagenesis (see "Results"), a striking difference was observed between the trigeminal nerves of the two strains. In EtNU-exposed BDIX rats, the frequency of mutant alleles drastically increased up to peak values of >90%, reflecting the development of full-blown schwannomas with loss of heterozygosity for the wild-type neu allele (clearly confirmed by the histomorphology of BDIX trigeminal nerves on day 180). In contrast, neu-mutant Schwann cells gradually disappeared from the BDIV trigeminal nerves, and the mutation became undetectable after day 220. Accordingly, the histomorphological appearance of BDIV trigeminal nerves on day 180 closely resembled that of untreated control animals.

The resistance of BDIV rats is thus apparently attributable to the elimination of neu-mutant premalignant cells. In most of the (BDIX x BDIV) F1 rats, too, neu-mutant cells disappeared during phases II and III. However, in accordance with the fact that ~20% of EtNU-exposed F1 rats developed trigeminal schwannomas (14) , a subgroup of F1 animals exhibited high levels of mutant alleles (up to 80%) in their trigeminal nerves through phase II. Because of, perhaps, a second event during oncogenesis [possibly BDIV allele-specific loss of heterozygosity on chromosome 10 (14) ], these neu-mutant cells may thus have been saved from the BDIV-specific control mechanisms.

Various mechanisms could be responsible for the removal of initiated cells. Among these are host factors such as immunosurveillance as well as tissue-specific processes. neu-mutant initiated Schwann cells within the trigeminal nerve could, for example, be removed by cytotoxic T cells or natural killer cells. Recent work by Altenschmidt et al. (21) has shown that syngeneically transplanted BDIX schwannoma cells do indeed induce a specific T-cell response; but they simultaneously secrete factors, such as transforming growth factor ß, which inhibit T-cell proliferation, thereby enabling schwannoma cells to escape immunosurveillance (21) . A differential capability of premalignant Schwann cells to escape immunosurveillance might translate into differential susceptibility.

Alternatively, neu-mutant cells in BDIV trigeminal nerves, contrary to their premalignant counterpart cells in BDIX rats, might be induced to undergo apoptosis at a rate exceeding their proliferation rate and thus ultimately disappear. If initiated BDIV Schwann cells undergo apoptosis at an elevated rate, the molecular stimuli triggering this response at >100 days after carcinogen exposure will have to be identified as well as apoptosis-associated genes that might be functionally polymorphic between BDIV and BDIX rats.

Redifferentiation of glutathione S-transferase 7-7 positive preneoplastic foci induced in the liver of resistant Copenhagen (Cop) rats has been suggested to be a putative resistance mechanism (18 , 22) . This option can be excluded for the disappearance of premalignant neu-mutant Schwann cells in the trigeminal nerves of BDIV rats. Mutant alleles are no longer detectable at 220 days after carcinogen exposure, even further distal to the nerve-brain junctional area. The premalignant cells must, therefore, have been eliminated from the nerve tissue rather than having migrated out or differentiated. Our ongoing studies are directed toward clarification of the mechanism(s) responsible for the elimination of premalignant Schwann cells by functional and morphological analyses.

A phenomenon similar to the one described here has been observed regarding the resistance of Cop rats to the induction of mammary tumors by N-methyl-N-nitrosourea (10) . After exposure to N-methyl-N-nitrosourea, Cop rats developed characteristic preneoplastic lesions after a period of time corresponding to the time seen in the susceptible Wistar Furth (WF) strain. In this model, the cells of many lesions displayed an activating mutation of the Ha-ras gene in both the WF (75%) and the Cop rat (60%). Despite this fact, ras-mutant cells failed to progress toward malignancy and ultimately disappeared in the resistant strain (9 , 10) . Crosses with immune-deficient nude rats have shown that the resistance of Cop rats does not depend on the presence of T cells (23) .

Resistance to cancer development effected by the elimination of premalignant cells at postinitiation stages of carcinogenesis not only calls for clarification of the underlying mechanisms and identification of the responsible genes; it also invites cancer-preventive approaches based on the interference with intermediary stages in the process of carcinogenesis preceding the onset of the growth of malignant tumors.


   ACKNOWLEDGMENTS
 
We thank Claudia Lechleiter and Thomas Haberland for expert assistance with animal husbandry and Claudia Wacker for help with photographic documentation. We appreciate the skilled assistance of Ute Häusler in the preparation of the manuscript.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported by Wilhelm Sander-Stiftung Grant 94.009.3 (to M. F. R. and A. K-R.), the Dr. Mildred Scheel Stiftung für Krebsforschung, Grant W87/92/Ra 5 (to M. F. R.), and the National Foundation for Cancer Research, USA, through Krebsforschung International e.V. (to M. F. R.). Back

2 These authors contributed equally to this work. Back

3 To whom requests for reprints should be addressed, at Institute of Cell Biology (Cancer Research), University of Essen Medical School, Hufeland-Strasse 55, D-45122 Essen, Germany. Phone: 049-(0)201-723-2803; Fax: 049-(0)201-723-5905; E-mail: rajewsky{at}uni-essen.de Back

4 The abbreviation used is: EtNU, N-ethyl-N-nitrosourea. Back

5 A. Kindler-Röhrborn, B. U. Koelsch, and M. F. Rajewsky, unpublished results. Back

Received 12/13/99. Accepted 7/19/00.


   REFERENCES
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
 Discussion
 REFERENCES
 

  1. Balmain A., Nagase H. Cancer resistance genes in mice: models for the study of tumour modifiers. Trends Genet., 14: 139-144, 1998.[Medline]
  2. Ponder B. A. J. Inherited predisposition to cancer. Trends Genet., 6: 213-218, 1990.[Medline]
  3. Pierotti M. A., Dragani T. A. Genetics and cancer. Curr. Opin. Oncol., 4: 127-133, 1992.[Medline]
  4. Hsu L. C., Kennan W. S., Shepel L. A., Jacob H. J., Szpirer C., Szpirer J., Lander E. S., Gould M. N. Genetic identification of Mcs-1, a rat mammary carcinoma suppressor gene. Cancer Res., 54: 2765-2770, 1994.[Abstract/Free Full Text]
  5. Shepel L. A., Lan H., Haag J. D., Brasic G. M., Gheen M. E., Simon G. S., Hoff P., Newton M. A., Gould M. N. Genetic mapping of rat mammary carcinoma suppressor (Mcs) loci. Genetics, 149: 289-299, 1998.[Abstract/Free Full Text]
  6. Cormier R. T., Hong K. H., Halberg R. B., Hawkins T. L., Richardson P., Mulherkar R., Dove W. F., Lander E. S. Secretory phospholipase Pla2g2a confers resistance to intestinal tumorigenesis. Nat. Genet., 17: 88-91, 1997.[Medline]
  7. Jacoby R. F., Hohman C., Marshall D. J., Frick T. J., Schlack S., Broda M., Smutko J., Elliot R. W. Genetic analysis of colon cancer susceptibility in mice. Genomics, 22: 381-387, 1994.[Medline]
  8. Lu S. J., Chaulk E. J., Archer M. C. Formation and repair of O6-methylguanine and methylation of the Ha-ras proto-oncogene by N-methyl-N-nitrosourea are not associated with mammary tumor resistance in the Copenhagen rat. Carcinogenesis (Lond.), 13: 857-861, 1992.[Abstract/Free Full Text]
  9. Lu S-J., Archer M. C. Ha-ras oncogene activation in mammary glands of N-methyl-N-nitrosourea-treated rats genetically resistant to mammary adenocarcinogenesis. Proc. Natl. Acad. Sci. USA, 89: 1001-1005, 1992.[Abstract/Free Full Text]
  10. Korkola J., Archer M. C. Resistance to mammary tumorigenesis in Copenhagen rats is associated with the loss of preneoplastic lesions. Carcinogenesis (Lond.), 20: 221-227, 1999.[Abstract/Free Full Text]
  11. Druckrey H. Genotypes and phenotypes of ten inbred strains of BD-rats. Arzneim.-Forsch., 12: 1274-1278, 1971.
  12. Druckrey H., Landschütz C. A., Ivankovic S. Transplacentare Erzeugung maligner Tumoren des Nerven systems. II. Äthyl-nitrosoharnstoff (ÄNH) an 10 genetisch definierten Rattenstämmen. Z. Krebsforsch., 73: 371-386, 1970.
  13. Rajewsky M. F., Augenlicht L. H., Biessmann H., Goth R., Hülser D. F., Laerum O. D., Lomakina L. Y. Hiatt H. H. Watson J. D. Winston J. A. eds. . Origins of Human Cancer,, : 709-726, Cold Spring Harbor Laboratory Cold Spring Harbor 1977.
  14. Kindler-Röhrborn A., Kölsch B. U., Fischer C., Held S., Rajewsky M. F. Ethylnitrosourea-induced development of malignant Schwannomas in the rat: two distinct loci on chromosome 10 involved in tumor susceptibility and oncogenesis. Cancer Res., 59: 1109-1114, 1999.[Abstract/Free Full Text]
  15. Nikitin, A. Yu., Ballering, L. A. P., Lyons, J., and Rajewsky, M. F. Early mutation of the neu (erbB-2) gene during ethylnitrosourea-induced oncogenesis in the rat Schwann cell lineage. Proc. Natl. Acad. Sci. USA, 88: 9939–9943, 1991.
  16. Bargmann C. I., Hung M-C., Weinberg R. A. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell, 45: 649-657, 1986.[Medline]
  17. Perantoni A. O., Rice J. M., Reed C. D., Watatani M., Wenk M. L. Activated neu oncogene sequences in primary tumors of the peripheral nervous system induced in rats by transplacental exposure to ethylnitrosourea. Proc. Natl. Acad. Sci. USA, 84: 6317-6321, 1987.[Abstract/Free Full Text]
  18. Wood G., Korkola J. E., Lee V. M., Sarma D. S. R., Archer M. C. Resistance of Copenhagen rats to chemical induction of glutathione S-transferase 7-7 positive liver foci. Carcinogenesis (Lond.), 18: 1745-1750, 1997.[Abstract/Free Full Text]
  19. Müller R., Rajewsky M. F. Elimination of O6-ethylguanine from the brain, liver, and other rat tissues exposed to ethylnitrosourea at different stages of prenatal development. Cancer Res., 43: 2897-2904, 1983.[Abstract/Free Full Text]
  20. Nikitin, A. Yu., Jin, J-J., Papewalis, J., Prokopenko S. N., Pozharisski, K. M., Winterhager, E., Flesken-Nikitin, A., and Rajewsky, M. F. Wild type neu transgene counteracts mutant homologue in malignant transformation of rat Schwann cells. Oncogene, 12: 1309–1317, 1996.
  21. Altenschmidt U., Kahl R., Klundt E., Stöcklin E., Mihatch M., Weindel K., Groner B. Schwannoma cells induce a tumor cell-specific cytotoxic T-cell response upon transplantation into syngeneic rats but escape elimination through the secretion of immunosuppressive factors. Int. J. Cancer, 70: 542-550, 1997.[Medline]
  22. Wood G., Sarma D. S. R., Archer M. C. Resistance to the promotion of glutathione S-transferase 7-7-positive liver lesions in Copenhagen rats. Carcinogenesis (Lond.), 20: 1169-1175, 1999.[Abstract/Free Full Text]
  23. Korkola J., Wood G. A., Archer M. C. Resistance to chemically-induced mammary tumors in Copenhagen x nude-derived F2 athymic rats: evidence that T-cell immunity is not involved in Copenhagen resistance. Carcinogenesis (Lond.), 18: 53-57, 1997.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Cancer Res.Home page
K. M. Gering, J. A.M. Marx, K. Lennartz, C. Fischer, M. F. Rajewsky, and A. Kindler-Rohrborn
The Interaction Mode of Premalignant Schwann and Immune Effector Cells during Chemically Induced Carcinogenesis in the Rat Peripheral Nervous System Is Strongly Influenced by Genetic Background.
Cancer Res., May 1, 2006; 66(9): 4708 - 4714.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
B. U. Koelsch, A. Kindler-Rohrborn, S. Held, S. Zabel, and M. F. Rajewsky
Loss of heterozygosity in malignant rat schwannomas chemically induced in hybrids of inbred rat strains with differential tumor susceptibility
Carcinogenesis, June 1, 2002; 23(6): 1033 - 1037.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
G. A. Wood, J. E. Korkola, and M. C. Archer
Tissue-specific resistance to cancer development in the rat: phenotypes of tumor-modifier genes
Carcinogenesis, January 1, 2002; 23(1): 1 - 9.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kindler-Röhrborn, A.
Right arrow Articles by Rajewsky, M. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kindler-Röhrborn, A.
Right arrow Articles by Rajewsky, M. F.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation